Crucell confirms revenue forecast for 2009
Crucell NV expects that revenue and other operating income will increase by 20% in 2009, confirming that it does not expect to be materially affected by the global recession.
News
Evotec moves further into drug discovery, raises revenue guidance
Evotec AG has raised its revenue guidance for 2009 following the strong performance of its drug discovery business in the second quarter. Revenue for the year is now expected to be more than 40 million euros.
MediGene says Eligard drove first-half revenue increase
MediGene AG reported an increase in revenue in the first half of 2009, mainly generated from the commercialisation in Europe of its treatment for prostate cancer, Eligard.
Galapagos sees 30% rise in revenue in 2009
Galapagos NV expects to report revenue of 100 million euros in 2009, up by 30% from a year earlier on growth in income from its risk-sharing alliances with Big Pharma and from its service division.
Vernalis in $200 million oncology deal with GSK
Vernalis Plc said that it is entering an exclusive collaboration, option and licensing agreement with GlaxoSmithKline to research an undisclosed oncology target. The deal, including milestone payments, is valued at more than $200 million.
BioAlliance Pharma looks to grow its business in the US
BioAlliance Pharma SA plans to break into the US market with a treatment for patients who are susceptible to opportunistic infections because their immune systems have been compromised.
DiaGenic raises NOK 9.35 million in share placement
DiaGenic ASA said that it has raised NOK 9.35 million ($1.54 million) through the placement of 2.5 million new shares with investors at a price of NOK 3.74 per share. The placement coincides with its plans to launch two diagnostic products in Europe.
An investor in London-listed Celsis is taking the firm private
An investor in Celsis International Plc, which makes products to detect drug toxicity, is taking the company private with a bid for the shares it does not already own pitched at 14.3% over the closing share price on 31 July 2009.
Crucell receives funding for its malaria vaccine technology
Crucell NV of the Netherlands said the US government has agreed to fund further clinical studies of its adenovirus-based vaccine technology against the malaria parasite, Plasmodium falciparum.
NicOx gives regulatory update for naproxcinod
NicOx SA has confirmed its plans to submit regulatory applications in the US and Europe by the end of 2009 for its anti-inflammatory agent, naproxcinod, which has been developed to relieve the signs and symptoms of osteoarthritis.